본문 바로가기
KERD
논문KCI 등재

H1975 세포에서 황금추출물에 의한 gefitinib 저항성 억제 효과

Root Extract of Scutellaria Baicalensis Increases Gefitinib Sensitivity in H1975 Human Non-small Cell Lung Cancer Cells

박현지|박신형
한의병리학회 (The Society of Pathology in Korean Medicine)|2021.08|동의생리병리학회지 (Journal of Physiology & Pathology in Korean Medicine)|제35권 제4호|pp. 117-123

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

ApoptosisScutellaria baicalensisNon-small cell lung cancerGefitinibEGFR TKI resistance
주제분류한의학

초록

Gefitinib, a first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), provides obvious clinical benefit in patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, patients ultimately develop gefitinib resistance which mainly caused by EGFR T790M secondary mutation. In the current study, we investigated whether the root extract of Scutellaria baicalensis (SB) overcomes gefitinib resistance. Gefitinib-resistant H1975 human NSCLC cells (EGFR L858R/​T790M double mutant) were treated with gefitinib and/or ethanol extract of SB (ESB) to evaluate the effect of ESB on the gefitinib sensitivity. The cell viability was measured by MTT assay and trypan blue exclusion assay. The colony-forming ability was evaluated by anchorage-dependent colony formation assay. Combined treatment with gefitinib and ESB markedly decreased the cell viability and colony formation than single treatment with gefitinib or ESB in H1975 cells. In addition, cells treated with both gefitinib and ESB exhibited a significant increase of sub-G1 DNA content which indicates apoptotic cells compared with those treated with gefitinib or ESB alone. As a molecular mechanism, combined treatment with gefitinib and ESB strongly downregulated the phosphorylation of ERK and JNK than single treatment with gefitinib or ESB. Taken together, our results demonstrate that ESB sensitizes H1975 cells to gefitinib treatment. We cautiously propose that ESB can be used in combination with gefitinib for the advanced NSCLC patients with acquired resistance to EGFR TKIs.

Abstract

Gefitinib, a first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), provides obvious clinical benefit in patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, patients ultimately develop gefitinib resistance which mainly caused by EGFR T790M secondary mutation. In the current study, we investigated whether the root extract of Scutellaria baicalensis (SB) overcomes gefitinib resistance. Gefitinib-resistant H1975 human NSCLC cells (EGFR L858R/​T790M double mutant) were treated with gefitinib and/or ethanol extract of SB (ESB) to evaluate the effect of ESB on the gefitinib sensitivity. The cell viability was measured by MTT assay and trypan blue exclusion assay. The colony-forming ability was evaluated by anchorage-dependent colony formation assay. Combined treatment with gefitinib and ESB markedly decreased the cell viability and colony formation than single treatment with gefitinib or ESB in H1975 cells. In addition, cells treated with both gefitinib and ESB exhibited a significant increase of sub-G1 DNA content which indicates apoptotic cells compared with those treated with gefitinib or ESB alone. As a molecular mechanism, combined treatment with gefitinib and ESB strongly downregulated the phosphorylation of ERK and JNK than single treatment with gefitinib or ESB. Taken together, our results demonstrate that ESB sensitizes H1975 cells to gefitinib treatment. We cautiously propose that ESB can be used in combination with gefitinib for the advanced NSCLC patients with acquired resistance to EGFR TKIs.

참고문헌 (40)

  1. "National Cancer Information Center"[URL]
  2. Siegel RL, "Cancer Statistics, 2021", CA Cancer J Clin, 71(1), pp.7~33 (2021)
  3. Kris MG, "Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs", JAMA, 311(19), pp.1998~2006 (2014)
  4. Zhang YL, "The prevalence of EGFR mutation in patients with non-small cell lung cancer : a systematic review and meta-analysis", Oncotarget, 7(48), pp.78985~78993 (2016)
  5. Scaltriti M, "The epidermal growth factor receptor pathway : a model for targeted therapy", Clin Cancer Res, 12(18), pp.5268~5272 (2006)
  6. Mok TS, "Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361(10), pp.947~957 (2009)
  7. Wu YL, "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-lung 6) : an open-label, randomised phase 3 trial", Lancet Oncol, 15(2), pp.213~222 (2014)
  8. Chong CR, "The quest to overcome resistance to EGFR-targeted therapies in cancer", Nat Med, 19(11), pp.1389~1400 (2013)
  9. Tang ZH, "Osimertinib resistance in non-small cell lung cancer : Mechanisms and therapeutic strategies", Cancer Lett, 420, pp.242~246 (2018)
  10. van der Wekken AJ, "Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature", Crit Rev Oncol Hematol, 100, pp.107~116 (2016)
  11. Zhang XW, "Chinese Herbal Medicine for Advanced Non-Small-Cell Lung Cancer : A Systematic Review and Meta-Analysis", Am J Chin Med, 46(5), pp.923~952 (2018)
  12. He W, "Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small cell lung cancer", Zhongguo Zhong Yao Za Zhi, 42(13), pp.2591~2598 (2017)
  13. Hung HY, "The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment", Integr Cancer Ther, 16(1), pp.126~131 (2017)
  14. Yamaguchi O, "Hange-Shashin-to for preventing diarrhea during afatinib therapy", Gan To Kagaku Ryoho, 42(5), pp.581~583 (2015)
  15. Yang XB, "Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations : study protocol for a randomized controlled trial", Trials, 16, pp.146~ (2015)
  16. Yang XB, "Effect of gefitinib plus Chinese herbal medicine(CHM)in patients with advanced non-small-cell lung cancer : a retrospective case-control study", Complement Ther Med, 22(6), pp.1010~1018 (2014)
  17. Liu ZL, "Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer : a systematic review and meta-analysis", J Integr Med, 12(4), pp.346~358 (2014)
  18. Zhao T, "Scutellaria baicalensis Georgi. (Lamiaceae): A review of its traditional uses, botany, phytochemistry, pharmacology and toxicology", J Pharm Pharmacol, 71(9), pp.1353~1369 (2019)
  19. Cheng CS, "Scutellaria baicalensis and Cancer Treatment : Recent Progress and Perspectives in Biomedical and Clinical Studies", Am J Chin Med, 46(1), pp.25~54 (2018)
  20. Kim HI, "Scutellaria Radix Promotes Apoptosis in Non-Small Cell Lung Cancer Cells via Induction of AMPK-Dependent Autophagy", Am J Chin Med, 47(3), pp.691~705 (2019)
  21. Gao J, "The ethanol extract of Scutellaria baicalensis and the active com-pounds induce cell cycle arrest and apoptosis including upregulation of p53 and Bax in human lung cancer cells", Toxicol Appl Pharmacol, 254(3), pp.221~228 (2011)
  22. Park KI, "Korean Scutellaria baicalensis water extract inhibits cell cycle G1", S transition by suppressing cyclin D1 expression and matrix-metalloproteinase-2 activity in human lung cancer cells, 2011, pp.133(2), 634~641
  23. Wang Y, "Total flavonoid aglycones extract in Radix scutellariae inhibits lung carcinoma and lung metastasis by affecting cell cycle and DNA synthesis", J Ethnopharmacol, 194, pp.269~279 (2016)
  24. Hyun-Ji Park HJ, "The Root Extract of Scutellaria baicalensis Induces Apoptosis in EGFR TKI-Resistant Human Lung Cancer Cells by Inactivation of STAT3", Int J Mol Sci, 22(10), pp.5181~ (2021)
  25. Braicu C, "A Comprehensive Review on MAPK : A Promising Therapeutic Target in Cancer", Cancers(Basel), 11(10), pp.1618~ (2019)
  26. Ettinger DS, "2017, NCCN clinical practice guidelines in oncology", J Natl Compr Cancer Netw, 15(4), pp.504~535 (2017)
  27. Azuma K, "Phase II study of erlotinib plus tivantinib(ARQ 197)in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR TKI, gefitinib or erlotinib", ESMO Open, 1(4), pp.e000063~ (2016)
  28. Wu YL, "Phase(Ph)II safety and efficacy results of a singlearm ph ib", II study of capmatinib(INC280)+ gefitinib in patients(pts)with EGFR-mutated(mut), cMET-positive(cMET+)non-small cell lung cancer(NSCLC), 2016, pp.34, 9020~
  29. Spigel DR, "Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer", J Clin Oncol, 31(32), pp.4105~4114 (2013)
  30. Mok T, "Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib(IMPRESS) : overall survival and biomarker analyses", J Clin Oncol, 35(36), pp.4027~4034 (2017)
  31. Goldberg SB, "Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors", Oncologist, 18(11), pp.1214~1220 (2013)
  32. Soria JC, "Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFRmutation-positive non-small-cell lung cancer after progression on first-line gefitinib(IMPRESS) : a phase 3 randomised trial", Lancet Oncol, 16(8), pp.990~998 (2015)
  33. Liao BC, "Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy", Lung Cancer, 110, pp.7~13 (2017)
  34. Lu Z, "ERK1", 2 MAP kinases in cell survival and apoptosis, 2006, pp.58(11), 621~631
  35. Lu Y, "Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway", Cancer Res, 80(21), pp.4655~4667 (2020)
  36. Li H, "Blocking the PI3K", AKT and MEK, Adv Med Sci, pp.2011, 56(2)[DOI]
  37. Wu Q, "JNK signaling in cancer cell survival", Med Res Rev, 39(6), pp.2082~2104 (2019)
  38. Itoh T, "IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells", Cell Death Dis, 12(6), pp.520~ (2021)
  39. Lee S, "Targeting MAPK Signaling in Cancer : Mechanisms of Drug Resistance and Sensitivity", Int J Mol Sci, 21(3), pp.1102~ (2020)
  40. Yeung YT, "Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization", EBioMedicine, 28, pp.51~61 (2018)

관련 논문AI추천

황금(Scutellaria. baicalensis Georgi) 추출물의 인체 유래 암세포주에 대한 항증식 효과이재혁대한산업경영학회 · 산업융합연구2026 · 제24권 제1호Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer김윤식, 손창규, 유주영, 유화승, 이강욱, 이남헌, 이종훈, 조정효대한약침학회 · Journal of Pharmacopuncture2016 · 제19권 제3호Deoxypodophyllotoxin Inhibits Cell Growth and Induces Apoptosis by Blocking EGFR and MET in Gefitinib-Resistant Non-Small Cell Lung Cancer윤구, 곽아원, 김은애, 김한솔, 서지혜, 심정현, 오하나, 이미현, 조승식, Jung-Il Chae한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2021 · 제31권 제4호Alternative drug therapies are superior to epidermal growth factor receptor -targeted chemotherapeutic drug responses in non-small cell lung cancerAnisur Rahman Khuda-Bukhsh, Sourav Sikdar셀메드 세포교정의약학회 · 셀메드2013 · 제3권 제2호Apoptosis of Human Bladder Cancer Cells by an Ethanolic Extract of Scutellaria Baicalensis GEORGI Via Caspase and MAPK Signaling Pathways김병주, 김희진, 박현수, 심지환, 이수진한의병리학회 · 동의생리병리학회지2016 · 제30권 제2호Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib김동완, 김미소, 김범석, 김소연, 김슬기, 김태민, 안용운, 허대석대한암학회 · Cancer Research and Treatment2019 · 제51권 제3호
원문 보기